Sarah Ferguson, MD, FRCSC, discusses the rationale to conduct a population-based cohort study comparing the efficacy of minimally invasive surgery versus open surgery for radical hysterectomy in women with cervical cancer.
Durvalumab has received perioperative approval in the European Union in patients with resectable non–small cell lung cancer based on data from AEGEAN.
The European Commission approved trastuzumab deruxtecan for HR-positive, HER2-low or -ultralow metastatic breast cancer after at least 1 endocrine therapy.
Acalabrutinib was effective in a population of patients from China with relapsed/refractory CLL.
Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.
Sara Nunnery, MD, MSCI, discusses the impact of the approvals of T-DXd and Dato-DXd in HR-positive breast cancer and sequencing questions with ADCs.
Updated interim phase 2 data showed the clinical efficacy and safety of neoadjuvant darovasertib monotherapy in localized uveal melanoma.
Mazyar Shadman, MD, MPH, discusses the rationale and methodological framework of a network meta-analysis aimed at evaluating the comparative efficacy of BTK inhibitors in R/R…
Experts highlight the top presentations to watch for at the 2025 AUA Annual Meeting.
Experts discuss the role of chimeric antigen receptor T-cell therapy (CAR T) in the treatment landscape for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL), how…
Bartosz Chmielowski, MD, PhD, discusses the rationale for investigating oncolytic viruses in melanoma.
